BioCentury
ARTICLE | Company News

Zogenix, Covidien sales and marketing update

June 18, 2012 7:00 AM UTC

Zogenix and Covidien's Mallinckrodt LLC pharmaceuticals business partnered to co-promote Zogenix's migraine drug Sumavel DosePro sumatriptan injection in the U.S. The deal runs through June 30, 2014, and can be extended by six month increments. Zogenix, which will continue to record all product revenues of the sumatriptan injection delivered via the DosePro needle-free system, said the deal will double its reach to prescribers. Mallinckrodt will receive a quarterly service fee that is calculated as a percentage of sales over a baseline. ...